Aldeyra Therapeutics, Inc.
ALDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001341235
In the last 90 days, Aldeyra Therapeutics, Inc. insiders filed 3 open-market purchases and 0 sales; 107 institutions reported holding it in 13F filings for Q2 2026, worth $77.7M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:46 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Mar 9, 2023 | Mar 17, 2022 |
| Research and development | $25.7M | $48.2M | $29.5M | $47.3M | $44.9M |
| Selling, general and administrative | $9.60M | $11.9M | $13.3M | $15.4M | $11.3M |
| Operating income | -$35.3M | -$60.1M | -$42.8M | -$62.7M | -$56.2M |
| Interest expense | – | – | $2.07M | $1.69M | $1.74M |
| Income tax | $0 | $1.00K | $0 | $0 | $0 |
| Net income | -$33.8M | -$55.9M | -$37.5M | -$62.0M | -$57.8M |
| EPS, basic | $-0.56 | $-0.94 | $-0.64 | $-1.06 | – |
| EPS, diluted | $-0.56 | $-0.94 | $-0.64 | $-1.06 | – |
| Weighted shares, basic | 60.1M | 59.5M | 58.9M | 58.4M | – |
| Weighted shares, diluted | 60.1M | 59.5M | 58.9M | 58.4M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Mar 9, 2023 | Mar 17, 2022 |
| Cash and equivalents | $70.0M | $54.5M | – | $144.4M | $229.8M |
| Short-term investments | – | $46.6M | – | $29.9M | – |
| Total current assets | $71.8M | $104.1M | $147.8M | $181.0M | $232.8M |
| Property, plant and equipment | – | $0 | $5.76K | $19.3K | $32.5K |
| Total assets | $72.1M | $104.6M | $148.3M | $181.3M | $233.1M |
| Accounts payable | $158.5K | $180.5K | $1.34M | $133.6K | $1.02M |
| Short-term debt | $15.2M | $31.4K | $15.1M | $911.8K | – |
| Total current liabilities | $27.8M | $18.6M | $22.3M | $15.4M | $11.8M |
| Long-term debt | $0 | $15.0M | $0 | $14.9M | $15.5M |
| Total liabilities | $27.8M | $33.6M | $28.5M | $30.3M | $27.4M |
| Shareholders' equity | $44.3M | $71.0M | $119.8M | $151.0M | $205.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Mar 9, 2023 | Mar 17, 2022 |
| Operating cash flow | -$33.3M | -$43.2M | -$30.3M | -$56.6M | -$42.6M |
| Capital expenditures | – | – | $0 | $16.3K | $7.81K |
| Free cash flow | – | – | -$30.3M | -$56.7M | -$42.6M |
| Stock-based compensation | $6.09M | $7.97M | $5.75M | $8.29M | $7.11M |
| Investing cash flow | $47.7M | -$44.9M | $30.0M | -$30.0M | -$7.81K |
| Financing cash flow | $1.12M | -$171.4K | -$1.27M | $1.22M | $194.5M |
| Net change in cash | $15.5M | -$88.3M | -$1.60M | -$85.4M | $151.9M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 60.4M | +0.3% | SEC |
| Aug 4, 2026 | 60.3M | +0.7% | SEC |
| May 5, 2026 | 60.3M | +0.7% | SEC |
| Feb 27, 2026 | 60.2M | +0.8% | SEC |
| Oct 28, 2025 | 60.2M | +1.0% | SEC |
| Aug 5, 2025 | 59.9M | +0.8% | SEC |
| May 12, 2025 | 59.9M | +0.8% | SEC |
| Feb 26, 2025 | 59.7M | +1.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.